The cytokine TWEAK and its own receptor Fn14 have emerged as valuable targets for cancer therapy potentially. Treatment of mice bearing founded HT-29 xenografts with GrB-TWEAK demonstrated significant tumor development inhibition in comparison to automobile only (< 0.05). Both GrB-TWEAK and GrB-Fc-IT4 Brivanib (BMS-540215) shown significant tumor development inhibition when given to mice bearing orthotopic… Continue reading The cytokine TWEAK and its own receptor Fn14 have emerged as